FDA's New Pilot Program Clears Path for Artificial Intelligence Devices

The Food and Drug Administration has launched the TEMPO pilot program, allowing certain artificial intelligence-powered medical devices to enter the market.

Details of the TEMPO Pilot Program

The Food and Drug Administration continues to take new steps regarding the oversight of artificial intelligence-based medical devices that make care decisions.

The agency's launched TEMPO pilot program temporarily enables developers to bring their products to market.

Market Entry and Authorization Process

Artificial intelligence products belonging to Cadence and Limbic are among the four devices accepted into the agency's pilot program.

This program allows digital health companies to launch their products on the market without receiving marketing authorization.

Medicare ACCESS Model and Goals

The main goal of the pilot implementation is to increase the number of accessible technologies under the scope of the Medicare ACCESS model.

This model is an experiment aimed at paying for technologies that support the management of individuals with chronic conditions.

Real-World Artificial Intelligence Regulation

The program in question allows the agency and companies to test artificial intelligence regulations under real-world conditions.